Cicor reshapes production footprint after acquisitions

Cicor is divesting its Tunisia facility and launching an efficiency programme expected to deliver more than CHF10m in recurring annual EBITDA improvements, as the Swiss electronics manufacturing services group consolidates capacity after several acquisitions.

The Tunisia operation, which employs around 90 people, is being sold for approximately €1.3m plus adjustments, while customer relationships will remain with Cicor. North African production will be concentrated at the company’s Moroccan sites in Berrechid and Temara near Casablanca, where the former Éolane and Valtronic operations will also be folded into the existing footprint.

Production from Geneva, acquired from Mercury Systems, will transfer to Newport in the UK and Bronschhofen in Switzerland, while tool-making activity will move from Singapore to Batam in Indonesia. Cicor is also increasing capacity and productivity at its thin-film substrate operation in Wangs, Switzerland, where aerospace and defence demand has strengthened.

The programme will reduce around 220 positions, equivalent to roughly five per cent of group headcount, including the Tunisia divestment. One-time implementation costs are expected to sit in the mid-single-digit million Swiss franc range during 2026, mostly in the first half, with the group maintaining its financial guidance as benefits begin to feed through later in the year.

Following a period of rapid expansion, the reorganisation brings the operational footprint closer to Cicor’s higher-reliability work in defence, medical, and industrial electronics. The company’s recent French defence electronics programme placed it firmly in long-lifecycle, qualification-heavy manufacturing, where site capability, documentation discipline, and production continuity carry as much weight as unit cost.

European EMS providers are being squeezed between regionalisation and margin discipline. Customers want supply chains closer to end markets after years of component disruption, yet they also expect electronics manufacturers to absorb wage pressure, compliance costs, automation investment, and unpredictable component availability. A wider footprint is useful only where capacity is loaded with work that matches each site’s engineering capability and cost base.

Medical electronics is adding similar pressure, with manufacturers seeking controlled production environments and certifications that can support regulated programmes. The UK medical manufacturing certification secured by ESCATEC illustrates the same direction of travel: EMS companies are moving towards higher-value sectors where audit trails, process validation, and customer qualification create barriers to entry.

Production transfers in those markets are rarely straightforward. Moving work between sites can require customer approvals, process revalidation, documentation updates, test transfer, operator training, and renewed confidence in repeatability. In defence and medical electronics, a site change is not a logistics decision alone; it alters the manufacturing evidence base behind the product.

Cicor’s restructuring therefore tests both integration discipline and customer trust. If the transfers are completed without weakening delivery or qualification performance, the programme should give the group a leaner platform for high-reliability electronics growth. If execution drags, the cost savings could be offset by disruption in precisely the sectors where continuity is most valued.

The wider market lesson is visible across European electronics manufacturing. Regional capacity is becoming more selective, not simply larger. Companies with acquired sites are concentrating production around locations that can support engineering-heavy programmes, higher utilisation, and defensible customer relationships, while lower-efficiency operations face stronger scrutiny.